Novartis considers shutting 'purpose-built' respiratory site
This article was originally published in Scrip
Executive Summary
Novartis has told employees at its Horsham site in the UK that it has begun a consultation process on shutting down the respiratory disease research facility, as part of its global strategy to streamline its R&D. The move puts 371 jobs and 170 local contractors at risk.